Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2021-02-02 3:13 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BlackRock Inc. BLK | 2,591,711 6.2% | 935,470 (+56.48%) | View |
| 2021-02-01 5:41 pm Unchanged | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | JOHNSON & JOHNSON JNJ | 2,449,183 5.7% | 0 (Unchanged) | View |
| 2020-06-09 4:32 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BlackRock Inc. BLK | 1,656,241 4.8% | 94,284 (+6.04%) | View |
| 2020-06-08 4:04 pm Sale | 13D | PROTAGONIST THERAPEUTICS INC C PTGX | Lilly Ventures Fund I LLC | 1,559,060 4.5% | -540,422 (-25.74%) | View |
| 2020-05-22 4:30 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,200,000 6.39% | 2,200,000 (New Position) | View |
| 2020-02-14 4:09 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Venrock Healthcare Capital Partners II L.P. | 113,140 0.4% | -1,385,989 (-92.45%) | View |
| 2020-02-14 4:00 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | PERCEPTIVE ADVISORS LLC | 0 0% | -1,365,579 (Position Closed) | View |
| 2020-02-14 2:37 pm Sale | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BIOTECHNOLOGY VALUE FUND L P | 2,332,630 8.1% | -169,760 (-6.78%) | View |
| 2020-02-14 1:24 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | RTW INVESTMENTS LP | 2,459,988 9.04% | 273,331 (+12.50%) | View |
| 2020-02-14 06:19 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | FARALLON CAPITAL MANAGEMENT LLC | 2,853,098 9.9% | 471,998 (+19.82%) | View |
| 2020-02-07 11:28 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | FMR LLC | 4,080,967 14.999% | 453,065 (+12.49%) | View |
| 2020-02-07 08:45 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | BlackRock Inc. BLK | 1,561,957 5.7% | 1,561,957 (New Position) | View |
| 2019-12-16 11:06 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | RTW INVESTMENTS LP | 2,186,657 8.04% | 2,186,657 (New Position) | View |
| 2019-07-01 4:49 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | INTEGRATED CORE STRATEGIES (US) LLC | 811,066 3.5% | 811,066 (New Position) | View |
| 2019-06-17 4:05 pm Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Venrock Healthcare Capital Partners II L.P. | 1,499,129 6.4% | 1,499,129 (New Position) | View |